Both in Pharmaceuticals
Cartesian Therapeutics vs Akebia Therapeutics
Over the past year RNAC returned −19.6% and AKBA returned −75.3%; their daily moves had a correlation of 0.22.
RNAC −19.6% AKBA −75.3%Growth of $1, one year, split-adjusted
| Metric | RNAC | AKBA |
|---|---|---|
| Price | $6.45 | $0.7292 |
| Market cap | $195.1M | $202.1M |
| Today | −0.15% | +10.43% |
| 1 month | −10.9% | −17.7% |
| 6 months | −0.3% | −46.4% |
| Year to date | −10.5% | −54.7% |
| 1 year | −27.1% | −77.0% |
| Revenue growth (YoY) | −100.0% | −21.4% |
| Gross margin | — | 78.8% |
| Net margin | — | −18.1% |
| P/E (TTM) | — | — |
| Price / sales | 132.1× | 0.9× |
| Net cash | $94.8M | $106.0M |
| Dividend yield | — | — |
| Volatility (60d) | 49.5% | 92.1% |
| Short % of float | 15.6% | 8.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).